Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
AstraZeneca ( (GB:AZN) ) has provided an update.
AstraZeneca has announced its issued share capital with voting rights as of December 31, 2024, stands at 1,550,546,239 ordinary shares. This figure is crucial for shareholders to calculate and notify any changes in their interest in AstraZeneca under the UK’s financial regulations. This transparency in voting rights and capital structure is vital for maintaining compliance with the UK Financial Conduct Authority’s rules, potentially impacting investor relations and market trust.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK. It specializes in the discovery, development, and commercialization of prescription medicines, focusing on Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca’s innovative medicines are available in over 125 countries and used by millions of patients worldwide.
Average Trading Volume: 2,548,055
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £162.3B
See more insights into AZN stock on TipRanks’ Stock Analysis page.
